The identified genomic alterations may also include targetable alterations, which match to either an approved cancer therapy or a drug in a clinical trial.
Examples of actionable genomic alterations include chromosomal rearrangements of the three neurotrophic tyrosine receptor kinase genes (NTRK1, NTRK2, NTRK3) that encode tropomyosin receptor kinases (TRK). In TRK fusion cancer, the NTRK gene fuses with an unrelated gene, causing overexpression of the oncogenic TRK fusion protein. NTRK fusions occur in a broad range of tumor types with varying frequency and across both pediatric and adult patients.
SeraCare has developed reference material that contains 15 clinically-relevant NTRK fusions in a single reference sample and is compatible with different NGS testing methodologies.
Download this free poster to learn how highly-characterized, patient-like reference standards can be used to standardize testing across laboratories and clinical sites.
Offered Free by: SeraCare
See All Resources from: SeraCare